Otonomy can’t seem to shake its clinical demons. A phase 2 trial for a tinnitus treatment has struck out, forcing the company to call it quits on the drug and shift focus once more. | Otonomy can’t seem to shake its clinical demons. A phase 2 trial for a tinnitus treatment has struck out...